Co-mutation pattern, clonal hierarchy, and clone size concur to determine disease phenotype of SRSF2P95-mutated neoplasms

• Published in: Leukemia Vol. 35; no. 8; pp. 2371 - 2381
• Main Authors: Todisco, Gabriele, Creignou, Maria, Gallì, Anna, Guglielmelli, Paola, Rumi, Elisa, Roncador, Marco, Rizzo, Ettore, Nannya, Yasuhito, Pietra, Daniela, Elena, Chiara, Bono, Elisa, Molteni, Elisabetta, Rosti, Vittorio, Catricalá, Silvia, Sarchi, Martina, Dimitriou, Marios, Ungerstedt, Johanna, Vannucchi, Alessandro Maria, Hellström-Lindberg, Eva, Ogawa, Seishi, Cazzola, Mario, Malcovati, Luca
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01.08.2021; Nature Publishing Group
• Subjects: 45; 45/23; 631/67/1990/1673; 692/308/2056; Acute myeloid leukemia; Cancer Research; Critical Care Medicine; Genes; Genotype & phenotype; Genotypes; Hematology; Heterogeneity; Intensive; Internal Medicine; Janus kinase 2; Leukemia; Leukocytosis; Medicine; Medicine & Public Health; Monocytosis; Mutation; Myelodysplastic syndrome; Myelodysplastic syndromes; Myelofibrosis; Myeloid leukemia; Neoplasms; Oncology; Patients; Phenotypes; Regression analysis; Runx1 protein; Sideroblasts; Splicing factors; Tumors
• ISSN: 0887-6924; 1476-5551; 1476-5551
• DOI: 10.1038/s41375-020-01106-z

Somatic mutations in splicing factor genes frequently occur in myeloid neoplasms. While SF3B1 mutations are associated with myelodysplastic syndromes (MDS) with ring sideroblasts, SRSF2 P95 mutations are found in different disease categories, including MDS, myeloproliferative neoplasms (MPN), myelodysplastic/myeloproliferative neoplasms (MDS/MPN), and acute myeloid leukemia (AML). To identify molecular determinants of this phenotypic heterogeneity, we explored molecular and clinical features of a prospective cohort of 279 SRSF2 P95 -mutated cases selected from a population of 2663 patients with myeloid neoplasms. Median number of somatic mutations per subject was 3. Multivariate regression analysis showed associations between co-mutated genes and clinical phenotype, including JAK2 or MPL with myelofibrosis (OR = 26.9); TET2 with monocytosis (OR = 5.2); RAS-pathway genes with leukocytosis (OR = 5.1); and STAG2 , RUNX1 , or IDH1/2 with blast phenotype (MDS or AML) (OR = 3.4, 1.9, and 2.1, respectively). Within patients with SRSF2–JAK2 co-mutation , JAK2 dominance was invariably associated with clinical feature of MPN, whereas SRSF2 mutation was dominant in MDS/MPN. Within patients with SRSF2–TET2 co-mutation, clinical expressivity of monocytosis was positively associated with co-mutated clone size. This study provides evidence that co-mutation pattern, clone size, and hierarchy concur to determine clinical phenotype, tracing relevant genotype–phenotype associations across disease entities and giving insight on unaccountable clinical heterogeneity within current WHO classification categories.